

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Boan Biotech**  
**博安生物**

**Shandong Boan Biotechnology Co., Ltd.**

**山东博安生物技术股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6955)**

## **PROPOSED ADOPTION OF RESTRICTED SHARE UNIT INCENTIVE SCHEME**

The board (the “**Board**”) of directors (the “**Directors**”) of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) announces that on 28 April 2026, the Board resolved to propose the adoption of a restricted share unit incentive scheme (the “**Restricted Share Unit Incentive Scheme**”) for H shares of the Company.

The purpose of the Restricted Share Unit Incentive Scheme is to further enhance the Company’s long-term talent incentive framework, motivate core employees to contribute to the Company’s growth, and foster closer alignment of interests among the shareholders of the Company (the “**Shareholders**”), the Company and the management team, thereby supporting the Company’s sustainable and sound long-term development.

The Restricted Share Unit Incentive Scheme does not involve the grant of new shares of the Company. However, the Restricted Share Unit Incentive Scheme constitutes a share scheme funded by existing shares under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and shall be subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules. Therefore, the adoption of the Restricted Share Unit Incentive Scheme is not subject to approval of the Shareholders pursuant to the Listing Rules. Nonetheless, pursuant to the articles of association of the Company, the Restricted Share Unit Incentive Scheme and the related matters are subject to, among others, the approval of the Shareholders at the general meeting of the Company.

The proposed adoption of the Restricted Share Unit Incentive Scheme and the proposed authorisation to the Board and/or its authorised person(s) to handle all matters pertaining to the Restricted Share Unit Incentive Scheme are subject to the approval of Shareholders by way of special resolutions at a general meeting of the Company.

A circular containing, among other things, the details and key terms of the Restricted Share Unit Incentive Scheme together with the notice of the general meeting will be published on the website of Hong Kong Exchanges and Clearing Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.boan-bio.com](http://www.boan-bio.com)) in due course.

By Order of the Board  
**Shandong Boan Biotechnology Co., Ltd.**  
**Jiang Hua**  
*Chairlady, Chief Executive Officer and  
Executive Director*

Yantai, the People's Republic of China, 28 April 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.*